UA61917C2 - Гранулят та композиція, що швидко розпадаються та швидко розчинюються - Google Patents
Гранулят та композиція, що швидко розпадаються та швидко розчинюються Download PDFInfo
- Publication number
- UA61917C2 UA61917C2 UA99020610A UA99020610A UA61917C2 UA 61917 C2 UA61917 C2 UA 61917C2 UA 99020610 A UA99020610 A UA 99020610A UA 99020610 A UA99020610 A UA 99020610A UA 61917 C2 UA61917 C2 UA 61917C2
- Authority
- UA
- Ukraine
- Prior art keywords
- cellulose
- water
- tablets
- granulate
- granules
- Prior art date
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 77
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 229920002678 cellulose Polymers 0.000 claims abstract description 43
- 239000001913 cellulose Substances 0.000 claims abstract description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000004480 active ingredient Substances 0.000 claims abstract description 32
- 235000010980 cellulose Nutrition 0.000 claims description 41
- 229940079593 drug Drugs 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 33
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 23
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 23
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 23
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 23
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 13
- 239000000945 filler Substances 0.000 claims description 13
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 13
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 13
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 13
- 238000005550 wet granulation Methods 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000007884 disintegrant Substances 0.000 claims description 10
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 9
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 9
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 9
- 239000002904 solvent Substances 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 4
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 238000007873 sieving Methods 0.000 claims description 2
- 238000012876 topography Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 14
- 238000000034 method Methods 0.000 description 27
- 239000000126 substance Substances 0.000 description 18
- 239000000314 lubricant Substances 0.000 description 14
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 13
- 238000004090 dissolution Methods 0.000 description 12
- 229960004920 amoxicillin trihydrate Drugs 0.000 description 11
- 238000002156 mixing Methods 0.000 description 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
- 239000011230 binding agent Substances 0.000 description 8
- 235000003599 food sweetener Nutrition 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000003765 sweetening agent Substances 0.000 description 8
- WKJGTOYAEQDNIA-IOOZKYRYSA-N (6r,7r)-7-[[(2r)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 WKJGTOYAEQDNIA-IOOZKYRYSA-N 0.000 description 7
- 229960003022 amoxicillin Drugs 0.000 description 7
- 229960005361 cefaclor Drugs 0.000 description 7
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 7
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229930186147 Cephalosporin Natural products 0.000 description 5
- 229940124587 cephalosporin Drugs 0.000 description 5
- -1 cephalosporin compound Chemical class 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 238000003825 pressing Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000001780 cephalosporins Chemical class 0.000 description 4
- 229960001680 ibuprofen Drugs 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229960005404 sulfamethoxazole Drugs 0.000 description 4
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 229940105329 carboxymethylcellulose Drugs 0.000 description 3
- 229960003405 ciprofloxacin Drugs 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 3
- 229960004306 sulfadiazine Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 2
- 239000003781 beta lactamase inhibitor Substances 0.000 description 2
- 229940126813 beta-lactamase inhibitor Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 238000005563 spheronization Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 239000002132 β-lactam antibiotic Substances 0.000 description 2
- 229940124586 β-lactam antibiotics Drugs 0.000 description 2
- 229940126085 β‑Lactamase Inhibitor Drugs 0.000 description 2
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001131 Pulp (paper) Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminum chloride Substances Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 229960000992 amodiaquine hydrochloride Drugs 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940121383 antituberculosis agent Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 229960003324 clavulanic acid Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 229940005501 dopaminergic agent Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 description 1
- 229960004144 josamycin Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 150000004957 nitroimidazoles Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000008023 pharmaceutical filler Substances 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- FDRCDNZGSXJAFP-UHFFFAOYSA-M sodium chloroacetate Chemical compound [Na+].[O-]C(=O)CCl FDRCDNZGSXJAFP-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960005053 tinidazole Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- General Preparation And Processing Of Foods (AREA)
- Jellies, Jams, And Syrups (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96201829 | 1996-07-03 | ||
| PCT/EP1997/003250 WO1998001114A1 (fr) | 1996-07-03 | 1997-06-19 | Granules destines a la preparation de compositions a haut pouvoir de desintegration et de dissolution, a teneur elevee en medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA61917C2 true UA61917C2 (uk) | 2003-12-15 |
Family
ID=8224133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA99020610A UA61917C2 (uk) | 1996-07-03 | 1997-06-19 | Гранулят та композиція, що швидко розпадаються та швидко розчинюються |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US5837292A (fr) |
| EP (1) | EP0910344B1 (fr) |
| JP (1) | JP4159607B2 (fr) |
| CN (1) | CN1131025C (fr) |
| AR (1) | AR008252A1 (fr) |
| AT (1) | ATE237314T1 (fr) |
| AU (1) | AU731276B2 (fr) |
| BG (1) | BG64114B1 (fr) |
| BR (1) | BR9710181B1 (fr) |
| CA (1) | CA2258841C (fr) |
| CO (1) | CO4890859A1 (fr) |
| CZ (1) | CZ295893B6 (fr) |
| DE (1) | DE69720995T2 (fr) |
| DK (1) | DK0910344T3 (fr) |
| EA (1) | EA001537B1 (fr) |
| EG (1) | EG23814A (fr) |
| ES (1) | ES2197351T3 (fr) |
| HK (1) | HK1021511A1 (fr) |
| HU (1) | HU225115B1 (fr) |
| ID (1) | ID17128A (fr) |
| IL (1) | IL127364A (fr) |
| JO (1) | JO1969B1 (fr) |
| MY (1) | MY116124A (fr) |
| NO (1) | NO320767B1 (fr) |
| NZ (1) | NZ333247A (fr) |
| PE (1) | PE89798A1 (fr) |
| PL (1) | PL188235B1 (fr) |
| PT (1) | PT910344E (fr) |
| SI (1) | SI0910344T1 (fr) |
| SK (1) | SK284175B6 (fr) |
| TN (1) | TNSN97114A1 (fr) |
| TR (1) | TR199802762T2 (fr) |
| TW (1) | TW473392B (fr) |
| UA (1) | UA61917C2 (fr) |
| WO (1) | WO1998001114A1 (fr) |
| ZA (1) | ZA975848B (fr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6129932A (en) * | 1997-09-05 | 2000-10-10 | Merck & Co., Inc. | Compositions for inhibiting platelet aggregation |
| DE19820801A1 (de) * | 1998-05-09 | 1999-11-25 | Gruenenthal Gmbh | Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten |
| US6177101B1 (en) | 1998-06-11 | 2001-01-23 | Pharmacia & Upjohn Company | Delavirdine high strength tablet formulation |
| IT1305308B1 (it) * | 1999-03-26 | 2001-05-04 | Biosint S P A | Granulato ad alto contenuto di l-carnitina o alcanoil-l-carnitina,particolarmente adatto alla produzione di compresse per compressione |
| EP1180022A4 (fr) * | 1999-05-14 | 2004-01-07 | Lilly Co Eli | Elaboration d'un produit pharmaceutique en vrac uniformement dissout |
| HU227070B1 (en) * | 1999-08-11 | 2010-06-28 | Egis Gyogyszergyar Nyilvanosan | Immediate release pharmaceutical composition containing ciprofloxacin and process for its production |
| AR028253A1 (es) * | 2000-03-16 | 2003-04-30 | Pfizer Prod Inc | Inhibidores de la glucogeno fosforilasa |
| FR2816507B1 (fr) * | 2000-11-16 | 2003-02-28 | Ethypharm Lab Prod Ethiques | Microgranules a base de principe actif, procede de fabrication et compositons pharmaceutiques integrant lesdits microgranules |
| US6733781B2 (en) | 2000-12-06 | 2004-05-11 | Wyeth | Fast dissolving tablet |
| US7799342B2 (en) * | 2000-12-06 | 2010-09-21 | Wyeth Llc | Fast dissolving tablet |
| JP2004522752A (ja) * | 2001-02-05 | 2004-07-29 | アール．ピー． シェーラー テクノロジーズ インコーポレイテッド | 薬学的活性剤の味を軽減するための方法および組成物 |
| EP1285649A1 (fr) * | 2001-08-23 | 2003-02-26 | Cimex AG | Comprimé dispersible à deux couches comprenant de l'amoxicilline et du clavulanate dans des couches séparées |
| BR0307516A (pt) * | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Formas de dosagem de liberação imediata contendo dispersões de uma droga sólida |
| US20030229101A1 (en) * | 2002-06-06 | 2003-12-11 | Sherman Bernard Charles | Tablets comprising ciprofloxacin hydrochloride |
| WO2004006917A1 (fr) * | 2002-07-16 | 2004-01-22 | Ranbaxy Laboratories Limited | Comprimes dispersibles pour administration par voie orale |
| WO2004014337A2 (fr) * | 2002-08-02 | 2004-02-19 | Ranbaxy Laboratories Limited | Procede de preparation d'un comprime dispersible de cephalexine |
| JP4702763B2 (ja) * | 2003-07-30 | 2011-06-15 | 塩野義製薬株式会社 | 結晶セルロースを含有する安定な錠剤 |
| US7838029B1 (en) * | 2003-07-31 | 2010-11-23 | Watson Laboratories, Inc. | Mirtazapine solid dosage forms |
| US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
| ES2655435T3 (es) * | 2003-09-12 | 2018-02-20 | Amgen Inc. | Formulación de disolución rápida de cinacalcet |
| US20050089558A1 (en) * | 2003-10-28 | 2005-04-28 | Alamo Pharmaceuticals, Llc | Compositions and methods for the co-formulation and administration of tramadol and propoxyphene |
| EP1681050A1 (fr) * | 2005-01-13 | 2006-07-19 | Strides Arcolab Limited | Composition pharmaceutique dispersible avec libération prolongée |
| US7811604B1 (en) | 2005-11-14 | 2010-10-12 | Barr Laboratories, Inc. | Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same |
| US8617597B2 (en) | 2006-07-06 | 2013-12-31 | Bayer Intellectual Property Gmbh | Pharmaceutical composition containing a tetrahydrofolic acid |
| WO2008008120A1 (fr) * | 2006-07-14 | 2008-01-17 | Fmc Corporation | Forme solide |
| JP5201819B2 (ja) * | 2006-11-22 | 2013-06-05 | エスエス製薬株式会社 | 固形組成物 |
| US20080311162A1 (en) * | 2007-05-16 | 2008-12-18 | Olivia Darmuzey | Solid form |
| ES2758624T3 (es) * | 2009-02-12 | 2020-05-06 | Fuji Chem Ind Co Ltd | Composición de partículas desintegrantes y material de desintegración rápida moldeado por compresión que comprende la misma |
| EP2575777A1 (fr) * | 2010-06-03 | 2013-04-10 | Mahmut Bilgic | Formulation comprenant du cefpodoxime proxétil et de l'acide clavulanique |
| CN101912373B (zh) * | 2010-08-24 | 2012-01-04 | 北京京丰制药有限公司 | 稳定的头孢克洛分散片及其制备方法 |
| WO2013151517A1 (fr) * | 2012-04-04 | 2013-10-10 | Mahmut Bilgic | Formulations en comprimés comprenant du cefpodoxime proxétil et de l'acide clavulanique |
| JP2015063521A (ja) * | 2013-09-02 | 2015-04-09 | 科研製薬株式会社 | 高い薬物含有率を有する錠剤及びその製造方法 |
| CN106255512B (zh) | 2014-04-21 | 2021-01-01 | 株式会社大赛璐 | 含有微小纤维状纤维素的崩解性颗粒组合物 |
| CN110051639B (zh) * | 2019-03-15 | 2021-08-31 | 河北嘉迈医药科技有限公司 | 一种快速崩解型尼麦角林片及其制备方法 |
| CN117683469A (zh) * | 2023-10-24 | 2024-03-12 | 绍兴拓邦新能源股份有限公司 | 一种晶硅片背面碱抛光固态添加剂及其制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1322306A (en) * | 1971-04-15 | 1973-07-04 | Meiji Seika Co | Stabilized antibiotic preparation and manufacturing process therefor |
| BE795766A (fr) * | 1972-02-22 | 1973-08-22 | Lilly Co Eli | Particules de napsylate de propoxyphene retard et procede de fabrication de ces particules |
| DE2259646C2 (de) * | 1972-12-06 | 1984-11-22 | Hoechst Ag, 6230 Frankfurt | Hochdosierte Tabletten von Cephalosporin-Derivaten sowie Verfahren zu ihrer Herstellung |
| GB1509866A (en) * | 1975-06-10 | 1978-05-04 | Johnson & Johnson | Enteric coated digestive enzyme compositions |
| JPS58403B2 (ja) * | 1975-07-24 | 1983-01-06 | 武田薬品工業株式会社 | Ｌ− アスコルビンサンセイザイノ セイゾウホウ |
| NL184308C (nl) * | 1975-07-24 | 1989-06-16 | Takeda Chemical Industries Ltd | Werkwijze voor het bereiden van l-ascorbienzuurgranules. |
| GB1560475A (en) * | 1975-10-11 | 1980-02-06 | Lilly Industries Ltd | Pharmaceutical formulation |
| GB1561301A (en) * | 1976-01-02 | 1980-02-20 | Beecham Group Ltd | Orally administrable pharmaceutical composition |
| HU187215B (en) * | 1983-01-26 | 1985-11-28 | Egyt Gyogyszervegyeszeti Gyar | Method for producing pharmaceutical product of high actor content and prolonged effect |
| EP0200252B1 (fr) * | 1985-05-02 | 1999-03-10 | Yamanouchi Europe B.V. | Comprimés contenant de la triméthoprime et un sulfonamide |
| GB8521350D0 (en) * | 1985-08-28 | 1985-10-02 | Euro Celtique Sa | Analgesic composition |
| EP0281200B1 (fr) * | 1987-03-02 | 1994-01-19 | Yamanouchi Europe B.V. | Composition pharmaceutique, granulé pharmaceutique et leur procédé de fabrication |
| DE68916983T2 (de) * | 1988-02-25 | 1995-01-19 | Yamanouchi Europ Bv | Verfahren zur Herstellung eines pharmazeutischen Granulats. |
| US4911921A (en) * | 1989-02-02 | 1990-03-27 | Mallinckrodt, Inc. | High ibuprofen content granulations |
| GB9109862D0 (en) * | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| DE4122217C2 (de) * | 1991-07-04 | 1997-02-13 | Merz & Co Gmbh & Co | Verfahren zur Herstellung mechanisch stabiler, gut zerfallender Komprimate aus kleinen wirkstoffhaltigen Formkörpern |
| IL109097A0 (en) * | 1993-04-03 | 1994-06-24 | Knoll Ag | Delayed release micro tablet of beta-phenylpropiophenone derivatives and its production |
-
1996
- 1996-12-20 US US08/770,421 patent/US5837292A/en not_active Expired - Lifetime
-
1997
- 1997-06-19 UA UA99020610A patent/UA61917C2/uk unknown
- 1997-06-19 IL IL12736497A patent/IL127364A/xx not_active IP Right Cessation
- 1997-06-19 ES ES97929241T patent/ES2197351T3/es not_active Expired - Lifetime
- 1997-06-19 SI SI9730487T patent/SI0910344T1/xx unknown
- 1997-06-19 DK DK97929241T patent/DK0910344T3/da active
- 1997-06-19 WO PCT/EP1997/003250 patent/WO1998001114A1/fr active IP Right Grant
- 1997-06-19 PL PL97330958A patent/PL188235B1/pl unknown
- 1997-06-19 CA CA002258841A patent/CA2258841C/fr not_active Expired - Lifetime
- 1997-06-19 EA EA199900075A patent/EA001537B1/ru not_active IP Right Cessation
- 1997-06-19 AU AU33421/97A patent/AU731276B2/en not_active Expired
- 1997-06-19 CN CN97196057A patent/CN1131025C/zh not_active Expired - Lifetime
- 1997-06-19 NZ NZ333247A patent/NZ333247A/xx not_active IP Right Cessation
- 1997-06-19 CZ CZ19996A patent/CZ295893B6/cs not_active IP Right Cessation
- 1997-06-19 JP JP50470198A patent/JP4159607B2/ja not_active Expired - Lifetime
- 1997-06-19 EP EP97929241A patent/EP0910344B1/fr not_active Expired - Lifetime
- 1997-06-19 PT PT97929241T patent/PT910344E/pt unknown
- 1997-06-19 DE DE69720995T patent/DE69720995T2/de not_active Expired - Lifetime
- 1997-06-19 BR BRPI9710181-8A patent/BR9710181B1/pt not_active IP Right Cessation
- 1997-06-19 TR TR1998/02762T patent/TR199802762T2/xx unknown
- 1997-06-19 SK SK1767-98A patent/SK284175B6/sk not_active IP Right Cessation
- 1997-06-19 AT AT97929241T patent/ATE237314T1/de active
- 1997-06-19 HU HU9903308A patent/HU225115B1/hu unknown
- 1997-06-24 TW TW086108821A patent/TW473392B/zh not_active IP Right Cessation
- 1997-06-30 JO JO19971969A patent/JO1969B1/en active
- 1997-06-30 ID IDP972281A patent/ID17128A/id unknown
- 1997-07-01 TN TNTNSN97114A patent/TNSN97114A1/fr unknown
- 1997-07-01 MY MYPI97002981A patent/MY116124A/en unknown
- 1997-07-01 PE PE1997000563A patent/PE89798A1/es not_active IP Right Cessation
- 1997-07-01 AR ARP970102930A patent/AR008252A1/es active IP Right Grant
- 1997-07-01 ZA ZA975848A patent/ZA975848B/xx unknown
- 1997-07-02 EG EG62397A patent/EG23814A/xx active
- 1997-07-03 CO CO97037091A patent/CO4890859A1/es unknown
-
1998
- 1998-12-28 NO NO986157A patent/NO320767B1/no not_active IP Right Cessation
- 1998-12-30 BG BG103047A patent/BG64114B1/bg unknown
-
2000
- 2000-01-28 HK HK00100533A patent/HK1021511A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA61917C2 (uk) | Гранулят та композиція, що швидко розпадаються та швидко розчинюються | |
| JP6092936B2 (ja) | 口腔内崩壊錠の製造方法 | |
| US20100016322A1 (en) | Water Dispersible Pharmaceutical Formulation and Process for Preparing The Same | |
| JPS63211224A (ja) | 水分散性錠剤 | |
| HU228399B1 (en) | Polymer coated tablet comprising amoxycillin and clavulanate, and process for producing them | |
| WO2001072285A1 (fr) | Granule facile a prendre | |
| JP2002514212A (ja) | セフアドロキシル一水和物錠剤処方物 | |
| CZ293718B6 (cs) | Způsob přípravy granulátu obsahujícího orálně účinné beta-laktamové antibiotikum a orální dávkovací forma obsahující orálně účinné beta-laktamové antibiotikum | |
| EP1539146A1 (fr) | Comprimes dispersibles pour administration par voie orale | |
| NZ511588A (en) | Compositions comprising cefuroxime axetil in a non gelatinous form when contacted with an aqueous liquid | |
| US20040037880A1 (en) | Extended release formulation of divalproex sodium | |
| US20060147517A1 (en) | Taste masking system for non-plasticizing drugs | |
| US20070059354A1 (en) | Sustained release dosage forms of oxcarbazepine | |
| JP4719899B2 (ja) | 口腔内速崩壊性錠剤 | |
| KR100475260B1 (ko) | 높은양의약을함유하는,신속-붕해되고신속-용해되는조성물제조용과립 | |
| WO2009130715A1 (fr) | Compositions orales de tramadol se désintégrant rapidement | |
| KR20060058415A (ko) | 아목시실린 및 클라불란산 또는 그의 염의 혼합물 함유조성물 및 그의 제조방법 |